YD Bio Ltd
YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs. The company is based in Taipei, Taiwan.
YD Bio Ltd (YDES) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.019x
Based on the latest financial reports, YD Bio Ltd (YDES) has a cash flow conversion efficiency ratio of 0.019x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-298.19K) by net assets ($-16.05 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
YD Bio Ltd - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how YD Bio Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
YD Bio Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of YD Bio Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jse Ltd
BE:JF6
|
N/A |
|
YOC - Dusseldorf Stock Exchang
DU:YOC
|
0.130x |
|
TREDEGAR
BE:T70
|
-0.008x |
|
Endurance RP Limited
PINK:RPGLF
|
0.514x |
|
IHYBF
OTCGREY:IHYBF
|
N/A |
|
MAZDA MOTOR CORP - Dusseldorf Stock Exchang
DU:MZA
|
0.119x |
|
Ismail Industries Limited
KAR:ISIL
|
N/A |
|
Top Win International Limited Ordinary Shares
NASDAQ:TOPW
|
N/A |
Annual Cash Flow Conversion Efficiency for YD Bio Ltd (2020–2024)
The table below shows the annual cash flow conversion efficiency of YD Bio Ltd from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $6.59 Million | $-1.84 Million | -0.279x | +88.49% |
| 2023-12-31 | $22.99K | $-55.66K | -2.421x | -796.73% |
| 2022-12-31 | $11.20 Million | $-3.02 Million | -0.270x | -4172.12% |
| 2021-12-31 | $108.96 Million | $-688.41K | -0.006x | -148.56% |
| 2020-12-31 | $99.78 Million | $-253.62K | -0.003x | -- |